Immunome (IMNM) Net Income (2019 - 2026)
Immunome's (IMNM) quarterly Net Income came in at -$244.2 million in Q1 2026, down 443.98% YoY from $71.0 million in Q1 2025, and down 235.2% on a QoQ basis from -$72.9 million in Q4 2025.
Immunome (IMNM) Net Income (2019 - 2026) Analysis & Trends
Immunome (IMNM) has 8 years of Net Income data on file, last reported at -$244.2 million in Q1 2026.
- Quarterly Net Income fell 443.98% year-over-year to -$244.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$489.3 million (down 48.04% YoY) and the FY2025 annual result came in at -$404.8 million, up 1.88% from the prior year.
- Net Income slipped to -$244.2 million in Q1 2026, from -$72.9 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$4.6 million in Q1 2023 to a low of -$244.2 million in Q1 2026.
- A 5-year average of -$66.2 million and a median of -$70.3 million in 2025 frame the typical range for Net Income.
- Annual changes were most pronounced in 2024 — Net Income tumbled 2796.5% — and 2025, when it surged 66.09%.
- Tracing IMNM's Net Income over 5 years: stood at -$8.1 million in 2022, then slumped by 1072.36% to -$94.7 million in 2023, then increased by 12.08% to -$83.3 million in 2024, then rose by 12.49% to -$72.9 million in 2025, then tumbled by 235.2% to -$244.2 million in 2026.
- The last three Net Income figures came in at -$244.2 million (Q1 2026), -$72.9 million (Q4 2025), and -$101.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | -248.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -248.28 Mn |
| Mar 31, 2026 | -244.25 Mn |
| Dec 31, 2025 | -72.87 Mn |
| Sep 30, 2025 | -101.90 Mn |
| Jun 30, 2025 | -70.30 Mn |
| Mar 31, 2025 | -44.90 Mn |
| Dec 31, 2024 | -83.27 Mn |
| Sep 30, 2024 | -116.13 Mn |
| Jun 30, 2024 | -86.23 Mn |
| Mar 31, 2024 | -132.40 Mn |
| Dec 31, 2023 | -94.72 Mn |
| Sep 30, 2023 | -15.83 Mn |
| Jun 30, 2023 | -16.07 Mn |
| Mar 31, 2023 | -4.57 Mn |
| Dec 31, 2022 | -8.08 Mn |
| Sep 30, 2022 | -11.93 Mn |
| Jun 30, 2022 | -10.73 Mn |
| Mar 31, 2022 | -11.75 Mn |
| Dec 31, 2021 | -7.76 Mn |
| Sep 30, 2021 | -7.72 Mn |